China Blood Testing Market Size & Outlook, 2025-2030
The blood testing market in China is expected to reach a projected revenue of US$ 9,469.0 million by 2030. A compound annual growth rate of 12.3% is expected of China blood testing market from 2025 to 2030.
The China blood testing market generated a revenue of USD 4,797.9 million in 2024 and is expected to reach USD 9,469.0 million by 2030.
The China market is expected to grow at a CAGR of 12.3% from 2025 to 2030.
In terms of segment, glucose testing was the largest revenue generating test type in 2024.
Glucose testing is the most lucrative test type segment registering the fastest growth during the forecast period.
Blood testing market data book summary
Market revenue in 2024
USD 4,797.9 million
Market revenue in 2030
USD 9,469.0 million
Growth rate
12.3% (CAGR from 2025 to 2030)
Largest segment
Glucose testing
Fastest growing segment
Glucose testing
Historical data
2018 - 2023
Base year
2024
Forecast period
2025 - 2030
Quantitative units
Revenue in USD million
Market segmentation
Glucose testing, A1C testing, Direct LDL testing, Lipid panel testing, Prostate-specific antigen testing, COVID-19 testing, BUN testing, Vitamin D testing, Thyroid-stimulating hormone testing, Serum Nicotine / Cotinine testing, High sensitivity CRP testing, Testosterone testing, ALT testing, Cortisol testing, Creatinine testing, AST testing, Other blood tests
Key market players worldwide
Abbott Laboratories, Roche Holding AG ADR, Bio-Rad Laboratories Inc, BioMerieux SA, Quest Diagnostics Inc, Biomerica Inc, Becton Dickinson & Co, Siemens Healthineers AG ADR, Danaher Corp, Trinity Biotech PLC ADR
Other key industry trends
In terms of revenue, China accounted for 5.0% of the global blood testing market in 2024.
Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
In Asia Pacific, China blood testing market is projected to lead the regional market in terms of revenue in 2030.
China is the fastest growing regional market in Asia Pacific and is projected to reach USD 9,469.0 million by 2030.
China held the largest market share in 2020 owing to steady economic improvement, greater health awareness, rise in per capita disposable income, increase in healthcare expenditure, and rise in the prevalence of non-communicable diseases.
Various initiatives have been undertaken by government and nongovernment organizations to create awareness about the treatment options for these disorders. For instance, the CDC has initiated a project for reducing the consumption of sodium and tobacco to prevent COPD and cardiac disorders in China.
Governing authorities, including the State Council, have introduced policies to support the medical equipment industry of China. Engagement of companies such as Jiangsu Yuyue Medical Equipment & Supply and Hunan China Sun has intensified the competition in the country.
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to Blood Testing Market Outlook will help companies and investors design strategic landscapes.
Glucose Testing was the largest segment with a revenue share of 20.31% in 2024.
Horizon Databook has segmented the China blood testing market based on glucose testing, a1c testing, direct ldl testing, lipid panel testing, prostate-specific antigen testing, covid-19 testing, bun testing, vitamin d testing, thyroid-stimulating hormone testing, serum nicotine / cotinine testing, high sensitivity crp testing, testosterone testing, alt testing, cortisol testing, creatinine testing, ast testing, other blood tests covering the revenue growth of each sub-segment from 2018 to 2030.
China held the largest market share in 2020 owing to steady economic improvement, greater health awareness, rise in per capita disposable income, increase in healthcare expenditure, and rise in the prevalence of non-communicable diseases.
Various initiatives have been undertaken by government and nongovernment organizations to create awareness about the treatment options for these disorders. For instance, the CDC has initiated a project for reducing the consumption of sodium and tobacco to prevent COPD and cardiac disorders in China.
Governing authorities, including the State Council, have introduced policies to support the medical equipment industry of China. Engagement of companies such as Jiangsu Yuyue Medical Equipment & Supply and Hunan China Sun has intensified the competition in the country.
China Blood Testing Market Test Type Outlook (Revenue, USD Million , 2018-2030)
Glucose testing
A1C testing
Direct LDL testing
Lipid panel testing
Prostate-specific antigen testing
COVID-19 testing
BUN testing
Vitamin D testing
Thyroid-stimulating hormone testing
Serum Nicotine / Cotinine testing
High sensitivity CRP testing
Testosterone testing
ALT testing
Cortisol testing
Creatinine testing
AST testing
Other blood tests
Reasons to subscribe to Blood Testing Market Outlook databook
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Blood Testing Market Outlook databook
Our clientele includes a mix of Blood Testing Market Outlook companies, investment firms, advisory firms & academic institutions.
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the China Blood Testing Market Outlook, including forecasts for subscribers. This country databook contains high-level insights into China Blood Testing Market Outlook from 2018 to 2030, including revenue numbers, major trends, and company profiles.